FRACTION-RCC: innovative, high-throughput assessment of nivolumab plus ipilimumab (N plus I) for treatment-refractory advanced renal cell carcinoma (aRCC) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Loidl, W
  • Choueiri, TK
  • Kluger, H
  • George, S
  • Tykodi, SS
  • Kuzel, TM
  • Perets, R
  • Nair, S
  • Procopio, G
  • Carducci, M
  • Castonguay, V
  • Folefac, E
  • Lee, C-H
  • Hotte, Sebastien
  • Miller, WH
  • Saggi, SS
  • Gold, D
  • Motzer, RJ
  • Escudier, B

publication date

  • October 1, 2020